NCT02590952 A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02548390 Study of Intravenous RXDX-107 in Patients With Solid Tumors Status TERMINATED Phase PHASE1
NCT02541604 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02536469 HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors Status COMPLETED Phase PHASE1
NCT02534649 Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials Status RECRUITING Phase NA
NCT02517918 Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma Status COMPLETED Phase PHASE1
NCT02494596 A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02490475 A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02488330 An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study Status COMPLETED Phase PHASE3
NCT02476123 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02472977 Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT02471846 A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Status COMPLETED Phase PHASE1
NCT02466802 Study of Regorafenib and Sildenafil for Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02454010 A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer Status COMPLETED Phase PHASE1
NCT02449564 The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors Status COMPLETED Phase NA
NCT02449538 Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors Status COMPLETED Phase PHASE2